高雄醫學大學圖書館 |

語系/ Language: 繁體中文

登入

回首頁

Tumor microenvironment

Lee, Peter P.

Tumor microenvironment

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Tumor microenvironment/ edited by Peter P. Lee, Francesco M. Marincola.
其他作者:	Marincola, Francesco M.
出版者:	Cham :Springer International Publishing : : 2020.,
面頁冊數:	xxiv, 326 p. :ill., digital ; : 24 cm.;
提要註:	This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.
Contained By:	Springer eBooks
標題:	Immunology. -
電子資源:	https://doi.org/10.1007/978-3-030-38862-1
ISBN:	9783030388621

Tumor microenvironment
Tumor microenvironment[electronic resource] /edited by Peter P. Lee, Francesco M. Marincola. - Cham :Springer International Publishing :2020. - xxiv, 326 p. :ill., digital ;24 cm. - Cancer treatment and research,v.1800927-3042 ;. - Cancer treatment and research ;v. 144..

Preface -- Part I: Imaging of tumor microenvironment, In vivo Imaging -- New technologies to image tumors -- Part II: Immune landscapes and their biology, Systemic correlates of the tumor microenvironment -- Adaptive immunity and the tumor microenvironment -- The biology of immune active cancers and their regulatory mechanisms -- The biology of immune excluded cancers -- Immunoscore -- Part III: The tumor microenvironment and therapy, The Immune Landscape in Women Cancers -- Translational biomarkers, combination therapies and their relationship with immune landscapes -- Effects of radiation on the tumor microenvironment -- Challenges of CAR T cell therapy for solid tumors.

This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.

ISBN: 9783030388621

Standard No.: 10.1007/978-3-030-38862-1doiSubjects--Topical Terms:

187040
Immunology.

LC Class. No.: RC268.3 / .T866 2020

Dewey Class. No.: 616.994079

Tumor microenvironment
LDR:03043nam a2200337 a 4500 001 338628
003 DE-He213
005 20200807110200.0
006 m d
007 cr nn 008maaau
008 210622s2020 sz s 0 eng d
020 $a 9783030388621 $q (electronic bk.)
020 $a 9783030388614 $q (paper)
024 7 $a 10.1007/978-3-030-38862-1 $2 doi
035 $a 978-3-030-38862-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC268.3 $b .T866 2020
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994079 $2 23
090 $a RC268.3 $b .T925 2020
245 0 0 $a Tumor microenvironment $h [electronic resource] / $c edited by Peter P. Lee, Francesco M. Marincola.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xxiv, 326 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer treatment and research, $x 0927-3042 ; $v v.180
505 0 $a Preface -- Part I: Imaging of tumor microenvironment, In vivo Imaging -- New technologies to image tumors -- Part II: Immune landscapes and their biology, Systemic correlates of the tumor microenvironment -- Adaptive immunity and the tumor microenvironment -- The biology of immune active cancers and their regulatory mechanisms -- The biology of immune excluded cancers -- Immunoscore -- Part III: The tumor microenvironment and therapy, The Immune Landscape in Women Cancers -- Translational biomarkers, combination therapies and their relationship with immune landscapes -- Effects of radiation on the tumor microenvironment -- Challenges of CAR T cell therapy for solid tumors.
520 $a This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.
650 2 4 $2 96060 $a Immunology. $3 187040
650 1 4 $2 96060 $a Oncology. $3 273823
650 0 $a Cancer $x Immunological aspects. $3 465232
650 0 $2 96060 $a Tumors $x Immunological aspects. $3 262275
700 1 $a Marincola, Francesco M. $3 466983
700 1 $a Lee, Peter P. $3 466982
710 2 $2 97100 $a SpringerLink (Online service) $3 255133
773 0 $t Springer eBooks
830 0 $a Cancer treatment and research ; $v v. 144. $3 442736
856 4 0 $u https://doi.org/10.1007/978-3-030-38862-1
950 $a Medicine (Springer-11650)

筆 0 讀者評論

多媒體

評論

新增評論分享你的心得，請勿在此評論區張貼涉及人身攻擊、情緒謾罵、或內容涉及非法的不當言論，館方有權利刪除任何違反評論規則之發言，情節嚴重者一律停權，以維護所有讀者的自由言論空間。

Export

取書館別